Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a po...

Full description

Bibliographic Details
Main Authors: Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster
Format: Article
Language:English
Published: Nature Publishing Group 2020-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-17414-y

Internet

https://doi.org/10.1038/s41467-020-17414-y

Similar Items